Blueprint Medicines Corp., of Cambridge, Mass., said it closed its underwritten public offering of 5.75 million shares of its common stock at $25 each, including the exercise in full by the underwriters of their option to purchase additional shares of common stock. The company estimates net proceeds from the offering will be approximately $134.5 million, after deducting underwriting discounts and commissions and estimated offering expenses. Goldman, Sachs & Co., Morgan Stanley and Cowen and Co. acted as joint book-running managers for the offering and JMP Securities and Wedbush Pacgrow acted as co-managers.